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OBJECTIVE — To explore the prevalence of lipid abnormalities and their relationship with
albumin excretion and microalbuminuria in adolescents with type 1 diabetes.
RESEARCH DESIGN AND METHODS — The study population comprised 895 young
subjects with type 1 diabetes (490 males); median age at the baseline assessment was 14.5 years
(range 10–21.1), and median diabetes duration was 4.8 years (0.2–17). A total of 2,194 non-
fasting blood samples were collected longitudinally for determination of total cholesterol, LDL
cholesterol, HDL cholesterol, TG, and non-HDL cholesterol. Additional annually collected data
on anthropometric parameters, A1C, and albumin-to-creatinine ratio (ACR) were available.
RESULTS — Total cholesterol, LDL cholesterol, HDL cholesterol, and non-HDL cholesterol
were higher in females than in males (all P  0.001). A signiﬁcant proportion of subjects
presented sustained lipid abnormalities during follow-up: total cholesterol 5.2 mmol/l
(18.6%), non-HDL cholesterol 3.4 mmol/l (25.9%), TG 1.7 mmol/l (20.1%), and LDL
cholesterol 3.4 mmol/l (9.6%). Age and duration were signiﬁcantly related to all lipid param-
eters (P  0.001); A1C was independently related to all parameters (P  0.001) except HDL
cholesterol, whereas BMI SD scores were related to all parameters (P  0.05) except total
cholesterol. Total cholesterol and non-HDL cholesterol were independently related to longitu-
dinal changes in ACR (B coefﬁcient  SE): 0.03  0.01/1 mmol/l, P  0.009, and 0.32 
0.014/1mmol/l,P0.02,respectively.Overallmeantotalcholesterolandnon-HDLcholesterol
were higher in microalbuminuria positive (n  115) than in normoalbuminuric subjects (n 
780):totalcholesterol4.71.2vs.4.50.8mmol/l(P0.04)andnon-HDLcholesterol3.2
1.2 vs. 2.9  0.8 mmol/l (P  0.03).
CONCLUSIONS — In this longitudinal study of adolescents with type 1 diabetes, sustained
lipid abnormalities were related to age, duration, BMI, and A1C. Furthermore, ACR was related
tobothtotalcholesterolandnon-HDLcholesterol,indicatingapotentialroleinthepathogenesis
of diabetic nephropathy.
Diabetes Care 32:658–663, 2009
T
ype 1 diabetes is associated with an
increased risk for the development
of microvascular complications and
cardiovascular disease (1,2). Qualitative
and quantitative lipid abnormalities are
often present in subjects with type 1 dia-
betes and are related to glycemic control
(2). The relationship between dyslipide-
miaandcardiovasculardiseaseriskiswell
documented in adult diabetic popula-
tions, and treatment with lipid-lowering
drugs has been associated with reduced
cardiovascularevents(2).Clinicalandex-
perimental studies have highlighted the
potential role of dyslipidemia in the de-
velopment of microalbuminuria and dia-
beticnephropathy(3).Mesangial,tubulo-
interstitial, and glomerular changes in the
kidney have been associated with lipid
levels (3). In animal models of diabetes,
treatment of hyperlipidemia with statins
hasbeenassociatedwithreducedglomer-
ular injury (3).
Cross-sectional studies in humans
have suggested that raised lipid levels are
involvedinthepathogenesisandprogres-
sionofrenaldiseases(3),andtreatmentof
dyslipidemia can reduce albumin excre-
tion (3). In the Steno study, subjects who
developed microalbuminuria had higher
cholesterollevelsthansubjectswhodidnot
progress(4).Inaddition,inthisstudy,asin
others, lower cholesterol levels predicted
regression of microalbuminuria to nor-
moalbuminuria (5). TG have also emerged
as a predictor for the development and
progression of renal complications (6).
Based on these data, it appears that mea-
surement of plasma lipids can add to the
prognostic value of albumin excretion in
the prediction of subjects at risk of dia-
betic nephropathy.
However, there is a lack of longitudi-
nal studies, particularly in young people
with type 1 diabetes, assessing the associ-
ation between lipid abnormalities and
risk for microalbuminuria. Based mainly
on cross-sectional studies, dyslipidemia
appears to be more common among
youth with diabetes than in the general
pediatric population (7,8), and its rela-
tionship with glycemic control has been
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trast, data on the association between
lipid levels and albumin excretion are
scant (11,12).
Therefore, the aim of the present
study was to assess the prevalence of lipid
abnormalities, their determinants, and
their relationship with albumin excretion
and the development of microalbumin-
uriainalargepopulationofyoungpeople
with type 1 diabetes, followed longitudi-
nally during puberty.
RESEARCH DESIGN AND
METHODS
Study population: Nephropathy
Family Study cohort
The Nephropathy Family Study (NFS) was
established between 2000 and 2005 as part
of the Juvenile Diabetes Research Founda-
tion/Wellcome Trust Diabetes Inﬂamma-
tion Laboratory: Genetic Resource
InvestigatingDiabetes(GRID)study(http://
www.childhood-diabetes.org.uk/grid.shtml).
Atotalof1,066subjects,aged10–16years,
who had developed type 1 diabetes before
theageof16years,wererecruitedthrough-
out four English regions (East Anglia, Bir-
mingham, Bristol, and Oxford). Subjects
with insulin-treated diabetes secondary to
other pathologies were excluded. Similarly,
childrenwithchronicrenaldiseaseorother
chronic diseases likely to affect renal func-
tionwereexcluded.Themediandurationof
follow-up is currently 2.3 years (interquar-
tile range 1.0–3.4).
The longitudinal study schedule
comprisedannualcollectionofthreecon-
secutive early-morning urine specimens
for centralized measurement of albumin-
to-creatinine ratio (ACR) and blood sam-
ples for measurements of A1C and lipids.
Ethical approval was obtained from
the regional ethics committee, and writ-
ten informed consent was obtained from
the parents together with assent from the
children.
Methods
Nonfasting blood samples, collected lon-
gitudinally between February 2001 and
January 2006, were analyzed for determi-
nation of total cholesterol, LDL choles-
terol,HDLcholesterol,triglycerides(TG),
and non-HDL cholesterol.
To exclude lipid abnormalities re-
lated to untreated diabetes, samples col-
lected within the ﬁrst month of diagnosis
were excluded. In addition, patients on
treatment with statins were also excluded
from the analysis.
A total of 2,194 lipid measurements
were available from 895 subjects; the
mean  SD number of measurements per
patient was 2.5  1.0 and the median 3
(range 1–5). A total of 183 subjects had
onlyonemeasurement,254hadtwomea-
surements, 333 had three measurements,
121 had four measurements, and only 4
subjects had ﬁve measurements.
A1C
Samples were analyzed centrally on a
TOSOH G7 analyzer, using high-per-
formance liquid chromatography and ab-
sorbance change detection and Diabetes
ControlandComplicationsTrial(DCCT)-
aligned methods. The normal range for
A1Cwas4.9–6.3%,andthecoefﬁcientof
variation(CV)was4.8and6.6%atalevel
of 5.5 and 10.1%, respectively.
Lipids
All samples were assayed centrally.
Measurements of total cholesterol, HDL
cholesterol, and TG were performed enzy-
matically on a Dimension RXL system
(Dade Behring) using reagents and cali-
brants supplied by the manufacturer. Be-
tween-run CVs were for total cholesterol
1.3% at 3.2 mmol/l and 1.2% at 7.5
mmol/l, for TG 3.2% at 1.0 mmol/l and
1.1% at 2.2 mmol/l, and for HDL choles-
terol 3.3% at 0.6 mmol/l and 2.1% at 1.5
mmol/l.
LDL cholesterol was calculated with
Friedwald’s formula: LDL  total choles-
terol  HDL cholesterol  TG/2.2.
Becauseoursampleswerecollectedin
nonfasting conditions, non-HDL choles-
terol(totalcholesterolminusHDLcholes-
terol) was also assessed.
Urinary albumin and creatinine
All urine samples were stored at 70°C
before the centralized analysis in a single
reference laboratory. Albumin was mea-
sured by a double antibody enzyme-
linked immunosorbent assay method.
The within and in-between assay CVs
were 6 and 12%, respectively. Creatinine
was measured using a modiﬁed Jaffe
method (Unimate 7, Roche Diagnostic
Systems, Basel, Switzerland) on a Cobas
Mira (Roche Diagnostic Systems) auto-
mated spectrophotometer. The CV was
2% at 2.2 mmol/l.
Calculations
BMI was calculated as weight/height
2.S D
scores for BMI were calculated using the
British1990GrowthReferenceandCole’s
LMS method.
ACR was summarized as the geomet-
ric mean of three consecutive early-
morning urine samples during each
annual assessment. The most recent ACR
measurements in relation to the time
when each lipid assessment was done
(within 3 months) was used for the
analyses of the relationship with lipid lev-
els. A total of 1,991 ACR measurements
were available from 870 subjects.
Microalbuminuria was deﬁned as an
ACR between 3.5 and 35 mg/mmol in
males and between 4.0 and 47 mg/mmol
in females in two of three consecutive
early-morningurinecollectionsduringan
annual assessment (13). Persistent mi-
croalbuminuria was deﬁned as an ACR
within the microalbuminuric range based
on two of three urines or two of two
urines each year for at least 2 consecutive
years. Transient microalbuminuria was
deﬁned as the presence of microalbumin-
uriafor1yearwithsubsequentregression
to normal.
Lipid levels were categorized, based
on the National Cholesterol Education
Programme (14) and American Heart As-
sociation (15) guidelines, as follow: high
total cholesterol: 5.2 mmol/l, border-
line total cholesterol: 4.4–5.2 mmol/l;
high LDL cholesterol: 3.4 mmol/l, bor-
derline LDL cholesterol: 2.9–3.4 mmol/l;
low HDL cholesterol: 0.9 mmol/l; high
TG: 1.7 mmol/l; high non-HDL choles-
terol: 3.4 mmol/l.
Statistical analysis
Data are summarized as means  SD or
median (range) for continuous variables
and as cell frequencies and percentages
for categorical variables. Non–normally
distributed variables (ACR and TG) were
log transformed before analysis. Compar-
isons between different groups were per-
formed by unpaired t tests. Comparisons
across categories were made using 
2 or
Fisher’s exact test. Correlations between
variables of interest were performed by
Pearson correlation. General linear mod-
els were used to assess longitudinal asso-
ciations between variables, which are
expressed as B coefﬁcient  SE.
RESULTS— The baseline characteris-
tics of the study population are shown in
Table 1. Age, duration of diabetes, and
age at diagnosis were similar between
male (n  490) and female (n  405)
subjects. No signiﬁcant differences were
found in glycemic control between sexes,
whereas BMI SD scores were signiﬁcantly
higher in females than in males. Levels of
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cholesterol, and non-HDL cholesterol
were higher in females than in males (all
P  0.001), whereas TG levels were com-
parable.Thesesexdifferencesinlipidlev-
els persisted after adjustment for BMI
(Table 1). Similar sex differences in lipid
parameters persisted during the subse-
quent follow-up visits (data not shown).
Categories of lipid levels at baseline
and during follow-up
A high prevalence of high and borderline
lipid levels was found at the baseline visit,
and these abnormalities persisted during
follow-up (see Fig. A1 in the online appen-
dix available at http://care.diabetesjournals.
org/cgi/content/full/dc08-1641/DC1). Mean
frequency of lipid abnormalities during
follow-up was as follows: total choles-
terol 18.6%, TG 20.1%, non-HDL cho-
lesterol 25.9%, LDL cholesterol 9.6%,
low HDL cholesterol 2.5%, borderline
total cholesterol 34.8%, and borderline
LDL cholesterol 12.7%.
Lipids and A1C
There was a signiﬁcant association be-
tween mean lipid levels, except HDL cho-
lesterol, and mean A1C (total cholesterol,
r  0.35; LDL cholesterol, r  0.21; TG,
r  0.40; non-HDL cholesterol,r  0.36;
all P  0.001). These associations were
signiﬁcantly stronger in girls than in boys
(total cholesterol, r  0.45 vs. 0.25, P 
0.01; LDL cholesterol, r  0.31 vs. 0.10,
P  0.01; TG, r  0.41 vs. 0.26, P 
0.05).
Longitudinal predictors of lipid
levels
A longitudinal evaluation of factors asso-
ciated with lipid levels was performed in
the 712 subjects with more than one lipid
assessment, with age, sex, duration of di-
abetes, A1C, and BMI SD score as the in-
dependent variables. In a covariate
model, age was signiﬁcantly related to all
lipid parameters; A1C was independently
related to all parameters except HDL cho-
lesterol, whereas BMI SD score was re-
lated to all parameters except total
cholesterol (Table 2). Similar results were
obtainedwhendurationwasincludedasa
covariate instead of age (data not shown).
The analysis was then repeated sepa-
rately for males and females, with similar
ﬁndings, except for the relationship be-
tween lipid levels and age, which per-
sisted in males but was no longer
signiﬁcant in females (data not shown).
Changes in lipids and albumin
excretion
We examined whether lipid parameters
predicted trends in albumin excretion
during follow-up. Table 3 shows the re-
sults of this analysis, before and after
adjusting for age, sex, duration, BMI SD
score, and A1C. Total cholesterol and
non-HDL cholesterol were indepen-
dently related to changes in log ACR
during follow-up.
During follow-up, 115 (13%) sub-
jects developed microalbuminuria (28
persistent and 87 transient microalbu-
minuria). Age-related changes in total
cholesterol and non-HDL cholesterol,
and speciﬁcally the rise in their levels after
the age of 15–16 years, were particularly
marked in subjects with persistent mi-
croalbuminuria when compared with indi-
viduals with transient microalbuminuria
and normoalbuminuria (Fig. 1).
Mean concentrations of total choles-
terol(4.71.2vs.4.50.8mmol/l,P
0.04) and non-HDL cholesterol (3.2 
1.2 vs. 2.9  0.8 mmol/l, P  0.03) were
higher in subjects developing microalbu-
minuriawhencomparedwithindividuals
with normoalbuminuria (see Table A1 in
theonlineappendix).However,thesedif-
Table 1—Baseline characteristics
All Male Female
n 895 490 405
Age at diagnosis (years) 9.6 (0.2–16.5) 9.8 (0.2–16.5) 9.5 (0.2–16.2)
Age at ﬁrst assessment (years) 14.5 (0.1–21.1) 14.6 (10.0–21) 14.5 (10.1–21.1)
Duration at ﬁrst assessment (years) 4.8 (0.2–17.0) 4.8 (0.2–16.9) 5.0 (0.2–17.0)
Age at microalbuminuria onset
(years) 15.6 (6.0–20.7) 15.3 (11.2–20.7) 15.9 (6.0–18.7)
BMI SD score 0.79  0.97 0.70  0.97 0.87  0.97
A1C (%) 9.3  1.9 9.2  1.8 9.4  1.9
Total cholesterol (mmol/l) 4.5  0.9 4.3  0.8 4.7  1.0*
HDL cholesterol (mmol/l) 1.6  0.4 1.6  0.4 1.7  0.4*
LDL cholesterol (mmol/l) 2.3  0.7 2.2  0.7 2.5  0.8*
TG (mmol/l) 1.0 (0.2–8.5) 1.0 (0.2–7.3) 1.0 (0.3–8.5)
Non-HDL cholesterol (mmol/l) 2.9  0.9 2.7  0.8 3.1  1.0*
Data are medians (range) and means  SD. *P  0.01 for females vs. males.
Table 2—Independent predictors of lipid levels during follow-up
B  SE P
Total cholesterol
Age (years) 0.042  0.014 0.004
A1C (%) 0.161  0.016 0.001
BMI SD score 0.077  0.043 NS
Log TG
Age (years) 0.018  0.005 0.001
A1C (%) 0.045  0.005 0.001
BMI SD score 0.062  0.014 0.001
HDL cholesterol
Age (years) 0.038  0.006 0.001
A1C (%) 0.001  0.007 NS
BMI SD score 0.06  0.019 0.001
LDL cholesterol
Age (years) 0.050  0.011 0.013
A1C (%) 0.072  0.013 0.001
BMI SD score 0.079  0.03 0.025
Non-HDL cholesterol
Age (years) 0.080  0.013 0.001
A1C (%) 0.160  0.015 0.001
BMI SD score 0.138  0.040 0.001
Data are from 712 subjects with more than one lipid measurement and are adjusted for repeated measure-
ments and sex.
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A1C. Microalbuminuria-positive subjects
also presented a high percentage of abnor-
mallipidlevels,speciﬁcallytotalcholesterol
and LDL cholesterol, when compared with
normoalbuminuric subjects.
CONCLUSIONS — In the present
study, we found a high prevalence of lipid
abnormalities in an adolescent population
with type 1 diabetes, diagnosed during
childhoodandfollowedlongitudinallydur-
ing puberty. Lipid levels were signiﬁcantly
inﬂuenced by age, duration of diabetes,
BMI, and glycemic control. In addition, we
found that total cholesterol and non-HDL
cholesterol were signiﬁcantly related to al-
bumin excretion during the study period.
In our study, the mean frequency of
high and borderline total cholesterol dur-
ing follow-up was 18.6 and 34.8%, re-
spectively. A large proportion of subjects
had high non-HDL cholesterol (25.9%),
whereas the frequency of low HDL cho-
lesterol was not particularly high (2.5%),
similar to ﬁndings from previous studies
(9). A high proportion of subjects had ab-
normal levels of TG and LDL cholesterol,
even though these parameters are less re-
liable, given that blood samples were col-
lected in nonfasting conditions.
Few data are available on lipid levels
inyoungpeoplewithtype1diabetes,and
the majority of studies have been cross-
sectional (7,8,16,17), with only a few being
longitudinal with short-term follow-up or a
retrospective design (9,18,19). In the
SEARCH study (16), one of ﬁve children
with type 1 diabetes presented total cho-
lesterol 5.2 mmol/l, similar to our re-
sults. Data from the Oxford Regional
Prospective Study showed that 15.3%
subjects had total cholesterol 5.2
mmol/l and 17.9% TG above 1.7 mmol/l
(12). Similar data have been reported in a
study from the U.S. where 15.2% of chil-
dren had high total cholesterol (7) and
from a German study where 28.6% of pa-
tients had dyslipidemia (8). Therefore, in
line with these studies, we conﬁrmed a
high prevalence of dyslipidemia in youth
with type 1 diabetes, and this is poten-
tially clinically signiﬁcant, given the well-
known relationship of dyslipidemia with
cardiovascular events (1) and the fact that
lipid levels frequently track from child-
hood to adulthood (20).
An overall increase in lipid parame-
ters with age was found in the present
study,andthiswasparticularlyevidentin
male subjects. However, our study shows
also a small but identiﬁable fall in choles-
terol around the age of 15–16 years, fol-
lowed by an increase thereafter. In
healthy adolescents, there is a decline of
10–20% in cholesterol levels during
puberty (21). This decline has been con-
stantly reported in boys, whereas in girls,
the picture has been more controversial,
since some studies have not shown any
pubertal decline in total cholesterol (22).
However,aninﬂuenceofageandpuberty
on lipid levels has not always been re-
ported in children and adolescents with
type 1 diabetes, and this is probably re-
latedtodifferencesintheagerangeacross
different studies (9,10,12). Lipid levels,
except TG, were higher in type 1 diabetic
girls than in boys. This is in line with pre-
vious data (8,23), and it might be related
to different degrees of insulin resistance
between the two sexes or to a direct effect
of the hormonal status on one or more
enzymesimplicatedinlipoproteinmetab-
olism (23).
Glycemic control signiﬁcantly inﬂu-
enced changes in lipid levels during fol-
low-up.Theonlyparameternotrelatedto
A1C was HDL cholesterol, similarly to
previous ﬁndings in adults (24). The lack
of a relationship between A1C and HDL
cholesterol could be due to opposite ef-
fects of glycemia on different HDL sub-
classes, which cannot be detected by
simply assessing total HDL cholesterol
(24). A strong relationship between other
lipid parameters and A1C was detected in
the DCCT as well as in studies more spe-
ciﬁcally targeting children and adoles-
cents with type 1 diabetes (7,9,10). The
adverse effect of glycemic control could
be due to glycation of lipoproteins, with
consequentreductionoftheircatabolism,
and to stimulation of transfer of cho-
lesteryl esters from HDL to apolipopro-
tein B–containing lipoproteins (2). The
strong relationship between lipid levels
andA1Cunderlinestheroleofgoodman-
agement of diabetes in controlling dyslip-
idemia. This is conﬁrmed by data from
theDCCT,whereintensivetreatmentwas
associated with a signiﬁcant reduction in
lipid levels (24). However, it is important
to acknowledge that, despite attempts to
improve glycemic control, the present
study and previous studies indicate that
the prevalence of lipid abnormalities is
high and persistent over time in youth
with type 1 diabetes (8,9), therefore sug-
gesting the possible need of additional in-
terventions with lipid-lowering drugs.
Inthepresentstudy,BMIwasanother
important determinant of lipid levels.
Previously, a similar association between
overweight and an adverse lipid proﬁle
was documented in subjects with type 1
diabetes (7,9). In the DCCT cohort, exces-
siveweightgainwasrelatedtodyslipidemia
and declines in A1C were associated with
improvements in lipid levels only in sub-
jects with the least weight gain during the
interventional period (25). These observa-
tions have been related to a state of insulin
resistance/hyperinsulinemia associated
with increased body weight (23).
The relationship between microalbu-
minuria and dyslipidemia has not been
extensively investigated in young people
with type 1 diabetes. In adult popula-
tions, increased total cholesterol and/or
TG have been associated with microalbu-
minuria (6), although associations with
lipidabnormalitieswerefoundtobemore
marked in patients with macroalbumin-
uria (6,23). With respect to the pediatric
populations with diabetes, data from the
Oxford Regional Prospective Study
showed that the prevalence of microalbu-
minuria increased across tertiles of total
cholesterol (12), and a recent German
study has shown a predictive value of
both LDL cholesterol and TG on the de-
velopment of persistent microalbuminuria
(11). In the present study, we examined
lipid levels in relation to changes in albu-
min excretion, as a continuous variable,
and the development of microalbumin-
uria. Increased total cholesterol and
non-HDL cholesterol levels were inde-
pendentlyrelatedtoACRduringfollow-up,
Table 3—Relationship between lipid parameters and ACR
B  SE* P*B  SE† P†
Total cholesterol 0.041  0.011 0.001 0.033  0.013 0.009
Log TG 0.12  0.033 0.001 0.072  0.037 NS
HDL cholesterol 0.006  0.026 NS 0.03  0.007 NS
LDL cholesterol 0.007  0.015 NS 0.002  0.016 NS
Non-HDL cholesterol 0.47  0.012 0.001 0.32  0.014 0.02
The dependent variable is log ACR. Regression coefﬁcients B are for each 1 mmol/l increase in lipid levels.
*Unadjusted values. †Adjusted values for age, sex, duration, BMI SD score, and A1C.
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and other confounding factors. In addition,
the changes in lipid levels with age in sub-
jects with persistent microalbuminuria
were remarkable when compared with
those with transient microalbuminuria or
normoalbuminuria. Both total cholesterol
andnon-HDLcholesterolshowedamarked
increase from the age of about 15 years in
Figure 1—Longitudinal changes in total cholesterol and non-HDL cholesterol with age in subjects with normoalbuminuria (MA) and in
individuals with transient and persistent microalbuminuria (MA).
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croalbuminuria. It is interesting that in our
study population the mean age at mi-
croalbuminuria onset was 15 years, there-
fore providing further support for a
potential relationship between lipid levels
and microalbuminuria. Overall, lipid levels
were higher in subjects developing mi-
croalbuminuria when compared with nor-
moalbuminuric subjects. However, these
differences were probably related to the
worseglycemiccontrolinsubjectswithmi-
croalbuminuria, since they disappeared
when adjusting for A1C.
In this longitudinal study of young
people with type 1 diabetes, we found
that lipid levels varied with age and were
higherinfemalesthaninmales.Lipidlev-
els were independently related to BMI,
and all parameters, except HDL choles-
terol, were also inﬂuenced by glycemic
control. A signiﬁcant number of subjects
presentedhighandborderlinelipidlevels
that persisted over time. Total cholesterol
andnon-HDLcholesterolwerecloselyre-
lated to albumin excretion during follow-
up, suggesting a potential role in the
pathogenesis of diabetic nephropathy.
Theseresultshighlighttheneedofscreen-
ing for dyslipidemia in adolescents with
type1diabetestoidentifyearlysubjectsat
riskforcomplications,whoneedmorein-
tensivefollow-upandperhapsotherther-
apeutic interventions.
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